Emperra's Bluetooth insulin pen and smartphone app in last CE approval stages

Emperra GmbH E-Health Technologies has announced that its integrated telemonitoring system — comprising of Bluetooth-enabled ESYSTA smart insulin pen and diabetes smartphone app — is almost ready for market launch. 

Both components are in the last stages of the CE conformity assessment procedure and will be available as an extension of the ESYSTA product system on the European market expectedly from late summer 2015.

Emperra developed the ESYSTA Bluetooth insulin pen for those diabetics who would like to send their data directly from the ESYSTA pen to their smartphone. It is equipped with a Bluetooth interface via which it communicates with the also newly developed ESYSTA app. Other Bluetooth enabled blood glucose meters can also be linked to the ESYSTA app. Further connections, like sensors for continuous glucose measurement, are under development. All data could be sent by the app to the clearly structured ESYSTA portal.

Dr. Christian Krey, CEO of Emperra, commented: "The further development of the already commercially available insulin-data transferring ESYSTA Smartpen to a Bluetooth enabled insulin pen is a logical step. By the direct transfer of the insulin data to a smartphone, a database is available at all times, that will further simplify the treatment. First diabetes centers and health insurers have already expressed their interest in providing their patients with the  ESYSTA Bluetooth pen.“

While the well-known mechanical solution for injection and the tested magnetic sensory for dosage record was adopted from the current ESYSTA pen, the type of data transfer will be adapted to Bluetooth low energy standards. This basically enables the connection to Bluetooth enabled smartphones, computers and even wearables (like smartwatches and measuring instruments for vital signs). The dosing accuracy for insulin of all current manufacturers will furthermore be guaranteed by the ESYSTA adapters. Well-known features that make life with daily insulin injections easier, like the automatic date and time set up or the global data access to the ESYSTA portal solution, are of course integrated.

The current ESYSTA pen, which allows insulin data and blood glucose values to be transferred wirelessly and made visible for the patient and the physician, will still be provided to patients who prefer easy solutions or are not willing or able to use devices like smartphones or computers.